{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:30:28Z","timestamp":1790739028545,"version":"4.1.0"},"reference-count":79,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs.<\/jats:p>","DOI":"10.1136\/bmjonc-2023-000287","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:35:23Z","timestamp":1706618123000},"page":"e000287","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending"],"prefix":"10.1136","volume":"3","author":[{"given":"Daniel A","family":"Goldstein","sequence":"first","affiliation":[{"name":"Medical Oncology, Rabin Medical Center Davidoff Cancer Center, Petah Tikva, Central, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B","family":"Saltz","sequence":"additional","affiliation":[{"name":"Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R","family":"Pond","sequence":"additional","affiliation":[{"name":"Biostatistics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2636-7041","authenticated-orcid":false,"given":"Ian F","family":"Tannock","sequence":"additional","affiliation":[{"name":"Medical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2025090109101566000_3.1.e000287.1","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/annonc\/mdw258","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"2025090109101566000_3.1.e000287.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx310"},{"key":"2025090109101566000_3.1.e000287.3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jamaoncol.2019.1341","article-title":"Interventional Pharmacoeconomics-A New Discipline for A Cost-Constrained Environment","volume":"5","author":"Ratain","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025090109101566000_3.1.e000287.4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cpt.1853","article-title":"Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value","volume":"108","author":"Serritella","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2025090109101566000_3.1.e000287.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1371"},{"key":"2025090109101566000_3.1.e000287.6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajhp\/59.6.529","article-title":"Prevalence and cost savings of therapeutic interchange among U.S. hospitals","volume":"59","author":"Schachtner","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"2025090109101566000_3.1.e000287.7","doi-asserted-by":"crossref","unstructured":"Kim C , Prasad V . Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration\u2019s Approval of Oncology Drugs. Mayo Clin Proc 2016. doi:10.1016\/j.mayocp.2016.02.012","DOI":"10.1016\/j.mayocp.2016.02.012"},{"key":"2025090109101566000_3.1.e000287.8","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1 Pt 2","key":"2025090109101566000_3.1.e000287.9","first-page":"468S","article-title":"Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors","volume":"9","author":"Buzdar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025090109101566000_3.1.e000287.10","unstructured":"Guidelines of the National comprehensive cancer network. Available: nccn.org [Accessed 31 Jul 2023]."},{"key":"2025090109101566000_3.1.e000287.11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41585-019-0186-2","article-title":"Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?","volume":"16","author":"Higano","year":"2019","journal-title":"Nat Rev Urol"},{"key":"2025090109101566000_3.1.e000287.12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2003892"},{"key":"2025090109101566000_3.1.e000287.13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdz397","article-title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","volume":"30","author":"Small","year":"2019","journal-title":"Ann Oncol"},{"key":"2025090109101566000_3.1.e000287.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342"},{"key":"2025090109101566000_3.1.e000287.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"2025090109101566000_3.1.e000287.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"2025090109101566000_3.1.e000287.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"2025090109101566000_3.1.e000287.18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/JU.0000000000001767","article-title":"Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer","volume":"206","author":"Halabi","year":"2021","journal-title":"J Urol"},{"key":"2025090109101566000_3.1.e000287.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.03.064"},{"key":"2025090109101566000_3.1.e000287.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-019-0121-y","article-title":"Are all cyclin-dependent kinases 4\/6 inhibitors created equal?","volume":"5","author":"Marra","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"2025090109101566000_3.1.e000287.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"2025090109101566000_3.1.e000287.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.353"},{"key":"2025090109101566000_3.1.e000287.23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025090109101566000_3.1.e000287.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05125-4"},{"issue":"17_suppl","key":"2025090109101566000_3.1.e000287.25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): Analyses from PALOMA-2","volume":"40","author":"Finn","year":"2022","journal-title":"JCO"},{"key":"2025090109101566000_3.1.e000287.26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090109101566000_3.1.e000287.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"2025090109101566000_3.1.e000287.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.009","article-title":"LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)","volume":"33","author":"Goetz","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025090109101566000_3.1.e000287.29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025090109101566000_3.1.e000287.30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02514"},{"key":"2025090109101566000_3.1.e000287.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00694-5"},{"issue":"17_suppl","key":"2025090109101566000_3.1.e000287.32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: Primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"JCO"},{"key":"2025090109101566000_3.1.e000287.33","first-page":"9071","article-title":"Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis","volume":"30","author":"Bas","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025090109101566000_3.1.e000287.34","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2073122"},{"key":"2025090109101566000_3.1.e000287.35","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.456"},{"key":"2025090109101566000_3.1.e000287.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"2025090109101566000_3.1.e000287.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70118-4"},{"key":"2025090109101566000_3.1.e000287.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"2025090109101566000_3.1.e000287.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2025090109101566000_3.1.e000287.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"2025090109101566000_3.1.e000287.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2025090109101566000_3.1.e000287.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2017.06.011"},{"key":"2025090109101566000_3.1.e000287.43","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24061190","article-title":"Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"2025090109101566000_3.1.e000287.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.2124"},{"key":"2025090109101566000_3.1.e000287.45","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1145"},{"key":"2025090109101566000_3.1.e000287.46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002872","article-title":"Competition and price among brand-name drugs in the same class: A systematic review of the evidence","volume":"16","author":"Sarpatwari","year":"2019","journal-title":"PLoS Med"},{"key":"2025090109101566000_3.1.e000287.47","unstructured":"Center for Medicare and Medicaid services. Available: https:\/\/www.cms.gov\/inflation-reduction-act-and-medicare\/medicare-drug-price-negotiation [Accessed 30 Oct 2023]."},{"key":"2025090109101566000_3.1.e000287.48","unstructured":"Anbefalinger for Onkologiske Og Kolonistimulerende Legemidler. Available: https:\/\/www.sykehusinnkjop.no\/siteassets\/avtaledokumenter\/avtaler-legemidler\/ Onkologi\/Onkologiske-og-kolonistimulerende-legemidler.pdf [Accessed 31 Jul 2023]."},{"key":"2025090109101566000_3.1.e000287.49","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025090109101566000_3.1.e000287.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3062"},{"key":"2025090109101566000_3.1.e000287.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.022"},{"key":"2025090109101566000_3.1.e000287.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2025090109101566000_3.1.e000287.53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"2025090109101566000_3.1.e000287.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2025090109101566000_3.1.e000287.55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"2025090109101566000_3.1.e000287.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2025090109101566000_3.1.e000287.57","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025090109101566000_3.1.e000287.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025090109101566000_3.1.e000287.59","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025090109101566000_3.1.e000287.60","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"2025090109101566000_3.1.e000287.61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2025090109101566000_3.1.e000287.62","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025090109101566000_3.1.e000287.63","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025090109101566000_3.1.e000287.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2025090109101566000_3.1.e000287.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"2025090109101566000_3.1.e000287.66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025090109101566000_3.1.e000287.67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"2025090109101566000_3.1.e000287.68","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30388-2"},{"key":"2025090109101566000_3.1.e000287.69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"2025090109101566000_3.1.e000287.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"2025090109101566000_3.1.e000287.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2025090109101566000_3.1.e000287.72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"2025090109101566000_3.1.e000287.73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6"},{"key":"2025090109101566000_3.1.e000287.74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"2025090109101566000_3.1.e000287.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380"},{"key":"2025090109101566000_3.1.e000287.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"2025090109101566000_3.1.e000287.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"2025090109101566000_3.1.e000287.78","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"2025090109101566000_3.1.e000287.79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2023-000287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:10:25Z","timestamp":1756743025000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2023-000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjonc-2023-000287"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2023-000287","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}